Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
- Conditions
- Interventions
- Biological: dactinomycinBiological: sargramostimDrug: carmustineDrug: cyclophosphamideDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: doxorubicin hydrochlorideDrug: methotrexateDrug: etoposideDrug: mercaptopurineDrug: prednisoneDrug: mitoxantrone hydrochlorideDrug: pegaspargaseDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 170
- Registration Number
- NCT00002766
- Locations
- 🇺🇸
Stanford Cancer Center at Stanford University Medical Center, Stanford, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 552
- Registration Number
- NCT00049595
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
🇧🇪Clinique Universitaire De Mont-Godinne, Yvoir, Belgium
🇦🇺Canberra Hospital, Garran, Australian Capital Territory, Australia
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Hoag Memorial Hospital Presbyterian
- Registration Number
- NCT00049413
- Locations
- 🇺🇸
Hoag Cancer Center at Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00028964
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 179
- Registration Number
- NCT00003650
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-01-21
- Target Recruit Count
- 1500
- Registration Number
- NCT00003728
- Locations
- 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷CHR de Besancon - Hopital Saint-Jacques, Besancon, France
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 59
- Registration Number
- NCT00003910
- Locations
- 🇺🇸
Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸McFarland Clinic, PC, Ames, Iowa, United States
Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00006390
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 33
- Registration Number
- NCT00003309
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville, Tennessee, United States
🇺🇸Medical College of Wisconsin Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 76
- Registration Number
- NCT00026208
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
🇺🇸Kaiser Permanente Medical Center, Vallejo, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.